Senate Finance Committee Opens Investigation Into Kratom Industry's Ties to Trump Cabinet

Why it matters

A senior U.S. senator is formally investigating whether kratom industry campaign contributions shaped DEA's decision to schedule synthetic 7-OH while leaving natural kratom products — and their politically connected manufacturers — untouched.

The big picture

The DEA's July 1 move to temporarily Schedule I only synthetic 7-OH products, not botanical kratom, immediately raised questions about who benefits. Reports that DHS Secretary Markwayne Mullin holds a financial stake in Botanic Tonics — maker of Feel Free, a leading natural-kratom beverage — prompted Senate Finance Ranking Member Ron Wyden to launch a formal congressional inquiry. The letter is the first formal congressional investigation tying kratom regulatory decisions to specific political relationships.

Key findings

• Botanic Tonics displayed a banner claiming 'FDA reinforces safety of natural leaf kratom' until July 1, 2026 — a statement the FDA calls false; the banner was removed the same day DEA announced 7-OH scheduling
• Sen. Wyden alleges DHS Secretary Mullin advocated for 7-OH restrictions while holding a financial stake in Botanic Tonics, a company that competes with 7-OH manufacturers
• Wyden wrote that Diversified Botanics CEO Ryan Niddel publicly described industry contributions to Trump officials as 'pay to have conversations' and 'pay to have a chance at the table'
• The Committee has jurisdiction over Medicare, Medicaid, CHIP, and dozens of healthcare programs burdened by addiction costs
• Botanic Tonics was given until August 31, 2026 to answer 17 questions about political contributions, meetings with cabinet officials, and product marketing practices
• Sen. Wyden noted the FDA continues to warn consumers not to use kratom, citing liver toxicity, seizures, and substance use disorder risks

What they say

"Scheduling decisions have far-reaching implications for public health, criminal justice, and ongoing scientific research. They are far too consequential to be influenced by partisan politics and campaign contributions," wrote Sen. Ron Wyden. "They should never be the subject of handshake deals between industry and the President's cabinet."

Bottom line

The Senate Finance Committee's formal investigation into Botanic Tonics is the most significant congressional action in kratom's regulatory history, directly connecting campaign contributions, cabinet-level conflicts of interest, and the DEA's decision to schedule synthetic 7-OH but spare natural kratom.